Briefe / Mitteilungen
Swiss Society for Infectious Diseases (SSI)
The Swiss Society for Infectious Diseases (SSI) and the Swiss Academic Foundation for Education in Infectious Diseases (SAFE-ID) will award 2 prizes each in the amount of 15 000 CHF for outstanding scientific achievements in basic research and in clinical research in infectious diseases during the 2017 annual meeting.
Eligibility: Authors of an outstanding scientific publication in basic or clinical research in infectious diseases. A significant part of the work must have been performed in Switzerland. The paper (or group of related papers) must have been either published or accepted for publication by an internationally renowned peer-reviewed journal between 17th July 2016 and 4th July 2017.
Conditions: Applications should be accompanied by a cover letter including the name and e-mail address of the applicant and the prize category applied for.
If the paper is accepted but not yet published please attach the letter of acceptance. The applicant must be an active member of the Swiss Society for Infectious Diseases (SSI). All authors agree with the application. A prize committee designated by the committee of the SSI performs the evaluation. Decisions made by the committee are definitive and not subject to appeals. The award is intended to support a research project of the awardee. The award is given to the applicant in person at the 2017 annual conference of the Swiss Society for Infectious Diseases that will be held from 30th August to 1st September 2017 at the Congress Center in Basel. The awardee is expected to give a short presentation of the work during the award ceremony on Thursday, 31st August, 5:30 pm. The award will be publicised in the Swiss medical press and on the websites of the SSI and the SAFE-ID.
Please submit the documents by e-mail to the president of the prize committee: Prof. Dr. med. Stephen Leib, Universität Bern, Institut für Infektionskrankheiten, Postfach,
Published under the copyright license
“Attribution – Non-Commercial – NoDerivatives 4.0”.
No commercial reuse without permission.